AN2 Therapeutics (ANTX) IPO Opens 13% Higher

Today's IPO for AN2 Therapeutics, Inc. (NASDAQ: ANTX) opened for trading earlier at $16.85 after its upsized initial public offering of 4,600,000 shares of its common stock at a price to the public of $15.00 per share. After dipping lower on the open, the stock has found some buyers and remains flat with the open.

The IPO was led by Cowen, SVB Leerink, and Evercore ISI.

AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The company is currently developing epetraborole, a once-daily oral treatment for patients with NTM lung disease.

You May Also Be Interested In

• SpaceX held talks to acquire AI coding startup Cognition - report
• Eightco reports $389M in holdings, repurchases 14M shares
• Performance Food Group to shrink board to 10 directors in 2026